- Home
- NEO
NEO
NeoGenomics Inc.
as 05-08-2025 4:00pm EST
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | FORT MYERS |
| Market Cap: | 1.2B | IPO Year: | 1999 |
| Target Price: | $13.31 | AVG Volume (30 days): | 3.1M |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.61 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.08 - $19.11 | Next Earning Date: | 04-29-2025 |
| Revenue: | $672,361,000 | Revenue Growth: | 10.10% |
| Revenue Growth (this year): | 13.05% | Revenue Growth (next year): | 11.18% |
Stock Insider Trading Activity of NeoGenomics Inc. (NEO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Zook Anthony P. | NEO | Chief Executive Officer | May 6 '25 | Buy | $7.88 | 18,900 | $148,918.77 | 18,900 | |
| Perez David Brian | NEO | Director | May 5 '25 | Buy | $7.63 | 10,000 | $76,300.00 | 10,000 | |
| Sherman Jeffrey Scott | NEO | Chief Financial Officer | May 2 '25 | Buy | $7.51 | 20,000 | $150,104.00 | 158,494 |
Latest NeoGenomics Inc. News
NEO Breaking Stock News: Dive into NEO Ticker-Specific Updates for Smart Investing
Argus Research
2 days ago
NEO: Raising target price to $6.00
Simply Wall St.
4 days ago
NeoGenomics First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
StockStory
4 days ago
3 Small-Cap Stocks Walking a Fine Line
MT Newswires
8 days ago
NeoGenomics Repays $201.3 Million Convertible Senior Notes
TipRanks
8 days ago
NeoGenomics price target lowered to $10 from $17 at Morgan Stanley
Business Wire
8 days ago
NeoGenomics Pays Off 1.25% Convertible Senior Notes
MT Newswires
9 days ago
Leerink Partners Downgrades NeoGenomics to Market Perform From Outperform, Lowers Price Target to $9 From $25
GuruFocus.com
9 days ago
NeoGenomics Inc (NEO) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Compare NEO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NEO NeoGenomics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.